Shining a Light on Lipid Nanoparticle Characterization

Published on: 
BioPharm International, BioPharm International, Emerging Therapies September 2022, Volume 2022 eBook, Issue 3
Pages: 22–25

Using an orthogonal approach to lipid nanoparticle analysis can increase the odds of project success.

The complexity of messenger RNA (mRNA)-based therapeutics is evident in the lipid nanoparticles (LNPs) used to encapsulate fragile mRNA cargo. Size, composition, aggregation, surface charge, and structure of LNPs can all have significant effects on a therapeutic molecule’s success. Unlike small-molecule drugs or protein therapeutics, which are chemically or biologically synthesized, LNPs self-assemble during the mixing of their component ingredients. This article discusses the challenges of LNP characterization as well as the analytical techniques that have proven successful in optimizing their development.

Read this article in BioPharm International’s September 2022 Emerging Therapies 2022 eBook.


About the authors

Hanna Jankevics Jones, PhD, and Natalia Markova, PhD, are pharmaceutical segment marketing managers at Malvern Panalytical.

Article Details

BioPharm International
eBook: Emerging Therapies 2022, September 2022
September 2022
Pages: 22–25


When referring to this article, please cite it as H.J. Jones and N. Markova, “Shining a Light on Lipid Nanoparticle Characterization," BioPharm International Emerging Therapies 2022 eBook (September 2022).